Analyst Price Targets — CLOV
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| October 21, 2025 8:11 am | Whit Mayo | Leerink Partners | $3.00 | $2.92 | StreetInsider | Clover Health (CLOV) PT Raised to $3 at Leerink Partners |
| December 17, 2024 12:18 pm | Matt Hewitt | Craig-Hallum | $6.00 | $3.16 | TheFly | Clover Health initiated with a Buy at Craig-Hallum |
| August 6, 2024 8:17 am | Richard Close | Canaccord Genuity | $2.50 | $1.86 | StreetInsider | Clover Health (CLOV) PT Raised to $2.50 at Canaccord Genuity |
| November 16, 2022 7:51 am | — | Citigroup | $1.80 | $1.44 | Benzinga | Citigroup Maintains Neutral on Clover Health Investments, Lowers Price Target to $1.8 |
Latest News for CLOV
CLOV rides strong membership growth and an AI-driven care model, but rising costs and policy risks cloud the near-term outlook.
WILMINGTON, Del., April 08, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that it will release its financial results after the market closes on Wednesday, May 6, 2026.
WILMINGTON, Del., April 07, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement company committed to bringing access to great healthcare to everyone on Medicare, in partnership with HealthEx , today announced a new collaboration that enables Clover Medicare Advantage (MA) members to securely access and share clinical records…
Clover Health Investments, Corp. (NASDAQ: CLOV - Get Free Report) saw unusually large options trading activity on Monday. Traders acquired 37,742 call options on the stock. This represents an increase of 42% compared to the average volume of 26,552 call options. Insider Buying and Selling at Clover Health Investments In related news, CEO Brady Patrick Priest
WILMINGTON, Del., April 01, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover” or the “Company”), a physician enablement company committed to bringing access to great healthcare to everyone on Medicare, today announced that Peter Kuipers is stepping down as the Chief Financial Officer of the Company, effective March 30, 2026. Mr. Kuipers will remain with the Company in an advisory…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CLOV.
U.S. House Trading
No House trades found for CLOV.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.